[go: up one dir, main page]

WO1990004977A3 - Traitement de condylomes genitaux a l'aide d'une combinaison d'azote liquide et d'interferon alpha humain d'adn de recombinaison - Google Patents

Traitement de condylomes genitaux a l'aide d'une combinaison d'azote liquide et d'interferon alpha humain d'adn de recombinaison Download PDF

Info

Publication number
WO1990004977A3
WO1990004977A3 PCT/US1989/004766 US8904766W WO9004977A3 WO 1990004977 A3 WO1990004977 A3 WO 1990004977A3 US 8904766 W US8904766 W US 8904766W WO 9004977 A3 WO9004977 A3 WO 9004977A3
Authority
WO
WIPO (PCT)
Prior art keywords
liquid nitrogen
recombinant dna
human alpha
alpha interferon
dna human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1989/004766
Other languages
English (en)
Other versions
WO1990004977A2 (fr
Inventor
Kenneth A Smiles
Edwin A Peets
Daniel J Tanner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Priority to KR1019900701395A priority Critical patent/KR900701309A/ko
Publication of WO1990004977A2 publication Critical patent/WO1990004977A2/fr
Publication of WO1990004977A3 publication Critical patent/WO1990004977A3/fr
Priority to DK079591A priority patent/DK79591A/da
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

On traite des infections dites condylomata acuminata (condylome anogénital) chez de patients infectés au moyen d'une thérapie combinée, c'est à dire par application d'azote liquide et immédiatement après par administration d'interféron alpha humain trois fois par semaine pendant trois semaines. La composition pharmaceutique d'interféron utilisée dans ladite thérapie combinée contient un interféron alpha-2b humain d'ADN de recombinaison dans lequel 1,0 x 106 unités internationales sont administre par injection dans chaque lésion. L'azote liquide est l'agent cryochirurgical pris à titre d'exemple, et que l'on applique localement à chaque lésion par des moyens classiques. L'invention concerne également l'emploi d'interféron alpha humain pour la fabrication d'un médicament utilisé dans la thérapie combinée prise comme exemple.
PCT/US1989/004766 1988-11-01 1989-10-30 Traitement de condylomes genitaux a l'aide d'une combinaison d'azote liquide et d'interferon alpha humain d'adn de recombinaison Ceased WO1990004977A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1019900701395A KR900701309A (ko) 1988-11-01 1989-10-30 액체 질소 및 재조합 DNA사람 α인터페론을 혼용하여 생식기우종을 치료하는 방법
DK079591A DK79591A (da) 1988-11-01 1991-04-30 Behandling af genitale vorter med en kombination af flydende nitrogen og rekombinant dna human alfa-interferon

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US265,612 1988-11-01
US07/265,612 US4959210A (en) 1988-11-01 1988-11-01 Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon

Publications (2)

Publication Number Publication Date
WO1990004977A2 WO1990004977A2 (fr) 1990-05-17
WO1990004977A3 true WO1990004977A3 (fr) 1990-06-28

Family

ID=23011173

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/004766 Ceased WO1990004977A2 (fr) 1988-11-01 1989-10-30 Traitement de condylomes genitaux a l'aide d'une combinaison d'azote liquide et d'interferon alpha humain d'adn de recombinaison

Country Status (12)

Country Link
US (1) US4959210A (fr)
EP (2) EP0445145A1 (fr)
JP (1) JPH03503766A (fr)
KR (1) KR900701309A (fr)
AU (1) AU636312B2 (fr)
CA (1) CA2001884A1 (fr)
DK (1) DK79591A (fr)
IL (1) IL92161A0 (fr)
MY (1) MY106603A (fr)
PH (1) PH26680A (fr)
WO (1) WO1990004977A2 (fr)
ZA (1) ZA898234B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5165921A (en) * 1989-01-23 1992-11-24 National Geno Sciences, Inc. Method for treating condyloma acuminatum with interferon
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
WO1992011025A2 (fr) * 1990-12-21 1992-07-09 Schering Corporation Administration d'interferon-alpha par inhalation orale pour le traitement de l'asthme et de maladies pulmonaires proliferatives non malignes
US6309662B1 (en) 1999-09-23 2001-10-30 Janet Buchanan Use of anti-inflammatory drugs for treatment of dermatological conditions
US7436227B2 (en) * 2003-05-02 2008-10-14 Silicon Laboratories Inc. Dual loop architecture useful for a programmable clock source and clock multiplier applications
WO2005074650A2 (fr) 2004-02-02 2005-08-18 Ambrx, Inc. Polypeptides a faisceau a quatre helices (4hb) humains modifies, et leur utilisation
RU2404743C2 (ru) * 2007-03-15 2010-11-27 Государственное образовательное учреждение высшего профессионального образования "Казанский государственный медицинский университет Росздрава" Способ лечения аногенитальных бородавок
US20110218241A1 (en) * 2010-03-06 2011-09-08 Cacao Bio-Technologies, Llc Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts
EP4019037A1 (fr) 2017-03-31 2022-06-29 Accanis Biotech F&E GmbH & Co KG Prévention et traitement de cancer de la peau non mélanique (nmsc)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503035B1 (en) * 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
US4286690A (en) * 1979-03-05 1981-09-01 Commercial Management Corporation Escape device
JPS59175416A (ja) * 1983-03-25 1984-10-04 Sunstar Inc 皮膚および粘膜の角化異常治療用外用剤
CA1321347C (fr) * 1986-11-10 1993-08-17 David C. Munch Composition d'interferon humain leucocytaire et traitement de la peau

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
H. HELWIG et al.: "Helwig Arzneimittel ein Handbuch fur Arzte und Apotheker", Vol. II, October 1988, 6th Edition, Wissenschaftliche Verlagsgesellschaft mbH, (Stuttgart, DE), pages 34-54 - 34-55 *

Also Published As

Publication number Publication date
ZA898234B (en) 1990-07-25
IL92161A0 (en) 1990-07-12
DK79591D0 (da) 1991-04-30
EP0445145A1 (fr) 1991-09-11
WO1990004977A2 (fr) 1990-05-17
KR900701309A (ko) 1990-12-01
EP0369632A1 (fr) 1990-05-23
AU636312B2 (en) 1993-04-29
PH26680A (en) 1992-09-15
AU4524689A (en) 1990-05-28
JPH03503766A (ja) 1991-08-22
CA2001884A1 (fr) 1990-05-01
DK79591A (da) 1991-06-14
MY106603A (en) 1995-06-30
US4959210A (en) 1990-09-25

Similar Documents

Publication Publication Date Title
CA2118121C (fr) Methodes et compositions pour traiter les maladies a l'aide de l'interferon tout en reduisant les effets secondaires
CA2245938A1 (fr) Therapie combinee pour l'elimination de l'arn du vhc decelable chez les patients atteints d'une infection chronique due au virus de l'hepatite c
IL141494A0 (en) Stable hypoxia inducible factor-1 alpha and method of use
WO2000037110A3 (fr) Traitement du vhc par induction d'interferon-alpha pegyle combine la ribavirine
RU95113492A (ru) Терапевтическая комбинация, содержащая человеческий интерферон, его применение, фармацевтический препарат, упаковка и способ лечения
CA2163112A1 (fr) Formulation pour facteur de coagulation viii
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
CA2186126A1 (fr) Formulation pharmaceutique servant a effectuer l'administration sous-cutanee, intramusculaire ou intradermique du facteur viii ou du facteur ix
ATE144704T1 (de) Mittel zur topischen verabreichung von arzneiwirkstoffen
EP1127577A3 (fr) Ligand pour le récepteur de c-kit et procédés d'utilisation
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
IL161889A (en) Use of omega interferon in the manufacture of a medicament for treating viral disease
WO1990004977A3 (fr) Traitement de condylomes genitaux a l'aide d'une combinaison d'azote liquide et d'interferon alpha humain d'adn de recombinaison
JP2002530353A5 (fr)
JP2003514025A5 (fr)
KR910005858A (ko) 지방산 요법
EP0393707A3 (fr) Composés bio-actifs associés à des liposomes et leur utilisation dans des préparations pharmaceutiques
ATE94763T1 (de) Medikament zur behandlung von fibrotischer stoerung und antifibrotische verbindung.
MY105798A (en) Treatment of leukocyte dysfunction with gm-csf.
WO2002058720A3 (fr) Dose unitaire de fgf-2 efficace sur le plan angiogenique et methode d'utilisation
MY105855A (en) Therapeutic nucleotides.
IE892261L (en) Therapeutic compounds
WO2000013701A3 (fr) Dose unitaire de fgf-2 a activite angiogenique efficace et procede d'utilisation
KR870010871A (ko) 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법
AR025549A1 (es) Mofetil micofelonato en asociacion con peg-ifn-alfa

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BB BG BR DK FI HU JP KP KR LK MC MG MW NO RO SD SU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR DK FI HU JP KP KR LK MC MG MW NO RO SD SU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1989912698

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989912698

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1989912698

Country of ref document: EP